Approves Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome. DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare neurodevelopmental disorder. We recognize the… Read More
Order your Copy Today! We are beyond excited to share the 2025 O.R.S.A. Calendar, where art, resilience, and community come together form coast to coast in the most beautiful way! Created by individuals with Rett syndrome and their amazing… Read More
Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada. We were honored to be… Read More
Tag: Acadia
DAYBUE – Breaking News
Last Updated: 10/17/2024 by Steve Leave a Comment
Approves Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome. DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare neurodevelopmental disorder. We recognize the… Read More
Category: Awareness, News, Top Slider Tags: 2024, Acadia, Trofinetide
2025 Calendars
Last Updated: 09/12/2024 by Steve Leave a Comment
Order your Copy Today! We are beyond excited to share the 2025 O.R.S.A. Calendar, where art, resilience, and community come together form coast to coast in the most beautiful way! Created by individuals with Rett syndrome and their amazing… Read More
Category: Fundraising, News, Top Slider Tags: 2024, Acadia, calendar
Priority Review by Health Canada
Last Updated: 10/25/2024 by Steve Leave a Comment
Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada. We were honored to be… Read More
Category: Latest Research, News, What's New Tags: 2024, Acadia, Health Canada